AstraZeneca PLC 552953CD1 Bond
AZNN Stock | MXN 1,384 6.50 0.47% |
AstraZeneca PLC holds a debt-to-equity ratio of 1.904. With a high degree of financial leverage come high-interest payments, which usually reduce AstraZeneca PLC's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
AstraZeneca PLC's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. AstraZeneca PLC's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps AstraZeneca Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect AstraZeneca PLC's stakeholders.
For most companies, including AstraZeneca PLC, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for AstraZeneca PLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, AstraZeneca PLC's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
AstraZeneca |
Given the importance of AstraZeneca PLC's capital structure, the first step in the capital decision process is for the management of AstraZeneca PLC to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of AstraZeneca PLC to issue bonds at a reasonable cost.
Popular Name | AstraZeneca PLC MGM Resorts International |
Equity ISIN Code | US0463531089 |
Bond Issue ISIN Code | US552953CD18 |
S&P Rating | Others |
Maturity Date | 1st of September 2026 |
Issuance Date | 19th of August 2016 |
Coupon | 4.625 % |
AstraZeneca PLC Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
ASTRAZENECA PLC 645 | US046353AD01 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
ASTRAZENECA PLC 3375 | US046353AL27 | Details | |
ASTRAZENECA PLC 4375 | US046353AM00 | Details | |
ASTRAZENECA PLC 4 | US046353AG32 | Details | |
ASTRAZENECA PLC 4 | US046353AT52 | Details | |
ASTRAZENECA PLC 4375 | US046353AU26 | Details | |
ASTRAZENECA PLC 3125 | US046353AN82 | Details | |
ASTRAZENECA PLC | US046353AV09 | Details | |
ASTRAZENECA PLC | US046353AW81 | Details | |
ASTRAZENECA PLC | US046353AZ13 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
AZN 4875 03 MAR 28 | US04636NAF06 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAE31 | Details | |
AZN 49 03 MAR 30 | US04636NAG88 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAA19 | Details | |
ASTRAZENECA FINANCE LLC | US04636NAB91 | Details | |
AZN 4875 03 MAR 33 | US04636NAH61 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
MGM Resorts International | US552953CD18 | Details |
Understaning AstraZeneca PLC Use of Financial Leverage
Understanding the structure of AstraZeneca PLC's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to AstraZeneca PLC's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 76100 people. Please read more on our technical analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.